

Index

Note: Page numbers in *italics* and **bold** refers to figures and tables respectively.

a

- AACVD. *see* aerosol-assisted chemical vapor deposition (AACVD)
- ABA. *see* aminophenylboric acid (ABA)
- absorption spectroscopy 543
- AC. *see* acetyl-cysteine (AC); acrylic emulsion (AC)
- acetylcholine (Ach) 426
- acetyl-cysteine (AC) 431
- Ach. *see* acetylcholine (Ach)
- acid proteases 204, 212
- acid red 88 (AR88) 23
- Acinetobacter baumannii* 454
- acne vulgaris 562
- ACQ. *see* aggregation-caused quenching (ACQ)
- acrylic emulsion (AC) 23
- “active attack” bactericidal strategy 92, 596
- active mechanisms. *see also* passive–active integrated mechanisms
- antimicrobial surfaces with 591
- contact-killing antimicrobial surfaces 591–593, **592**
- release-killing antimicrobial surfaces 593–596
- active responsiveness, antimicrobial surfaces with 605
- adenosine triphosphate (ATP) synthesis 52, 280
- adjuvants for enhanced antibiotic efficacy, cationic polymers as 64–66, 64
- advanced polymerization methods 41
- aerosol-assisted chemical vapor deposition (AACVD) 159
- AFM. *see* atomic force microscopy (AFM)
- Aggregatibacter actinomycetemcomitans* 467
- aggregation-caused quenching (ACQ) 389
- aggregation-induced emission (AIE) 389
- A-GNCs. *see* aminophenylboric acid-modified gold nanoclusters (A-GNCs)
- AI. *see* artificial intelligence (AI)
- AIE. *see* aggregation-induced emission (AIE)
- AKD. *see* alkyl ketene dimmer (AKD)
- alcalase 211
- alkali etching method 356
- alkaline phosphatase (ALP) 517
- alkaline proteases 204, 206, 211
- alkene monomers 37, **38–40**, 41
- alkyl ketene dimmer (AKD) 144
- alkyne monomers 42
- ALP. *see* alkaline phosphatase (ALP)
- α -amino acid polymers 190
- α -chymotrypsin 203
- α -defensins 180, **181**
- amidine-based cations 51–53
- amino acid hybrid polymers 191
- amino-based cations 50–51, 52
- aminoglycosides **231**, **241**, 560
- 5-aminolevulinic acid (ALA) 389
- amino-modified mesoporous silicon nanoparticles (AP-MSNs) 569
- aminophenylboric acid (ABA) 574
- aminophenylboric acid-modified gold nanoclusters (A-GNCs) 574
- ammonium persulfate (APS) 355
- amoxicillin 562
- AMP. *see* antimicrobial photothermal peptide (AMP)
- amphenicols **231**
- AMPs. *see* antimicrobial peptides (AMPs)
- AMR. *see* antimicrobial resistance (AMR)
- anodization 536
- ansamycins **231**
- “anti-adhesion to bactericidal” surfaces 99
- anti-adhesive and contact-killing mechanisms 597–599
- anti-adhesive and release-killing mechanisms 599–601
- anti-adhesive coatings 588, 588, **589**

Antimicrobial Materials and Interfaces: Synthesis, Characterization and Applications, First Edition.

Edited by En-Tang Kang, Liqun Xu and Peng Li.

© 2025 Wiley-VCH GmbH. Published 2025 by Wiley-VCH GmbH.

- anti-adhesive matrices 119
- antibacterial adhesion coating 153
- antibacterial agents 508–510
- antibacterial drugs 435
- antibacterial peptide-polymers
 - charge and residual functionalities 196–197
 - molecular size and architecture 197
 - physicochemical properties of 196
- antibacterial photothermal materials 421, 424
 - Ag-based PTMs 427
 - carbon-based photothermal materials 428–429
 - noble metal-based photothermal materials 425–427
 - organic photothermal materials 429–432
 - other photothermal materials 432–433
 - transition metal-based photothermal materials 427–428
- antibacterial photothermal therapy 421, 423–424
 - mechanism of 422
 - photothermal mechanism 422–423
 - PTMs for antibacterial applications 425
- antibacterial surface 88
 - and bactericidal property 91–99
 - zwitterion and antimicrobial peptide synergistic antibacterial surface 94, 96
 - zwitterion and metal synergistic antibacterial surface 94–97
 - zwitterionic and bactericide synergistic antibacterial surface 99, 99
 - zwitterionic and cationic polymer synergistic antibacterial surface 93–94, 93, 95
 - zwitterionic and nitric oxide synergistic antibacterial surface 97–98, 98
- antibacterial therapy 570–571
 - background of 484–485
 - overview of piezoelectric materials for 489–501
 - piezoelectric materials in 486–501
- antibiotics 229–230, 231–234, 449, 531, 553–554, 593
 - antibiotic-resistant bacterial infections 481
 - combination of antibiotics and other antimicrobials 565–566
 - conjugation of AMPs with 186, 188
 - gentamicin 374
 - pharmacokinetics of antibiotics to guide individualized dosing 560–561
- antifouling surfaces. *see* bacteria-resisting surfaces
- antimicrobial(s)
 - agents 435
 - in biofilms 558–560
 - materials 323
- antimicrobial nanometallics 239
 - antibiotics 229–230
 - antimicrobial resistance 230–236
 - bimetallic nanoparticles 249–250
 - copper oxide 247–248
 - emerging diseases based on mode of transmission 228
 - emerging diseases, causes of 228
 - future perspectives 250
 - gold nanoparticle 245–246
 - iron oxide 249
 - magnesium oxide 248
 - microbial menace 227–229
 - nanotechnology 236–239
 - nitric oxide 248
 - selenium oxide 249
 - silver nanoparticle 239–245
 - titanium oxide and titanium dioxide 247
 - zinc oxide 247
- antimicrobial peptides (AMPs) 92, 179, 553, 591
 - advantages and challenges of AMP-mimic polymers/polypeptides 197
 - amphiphilic structure 193–194
 - AMP-mimic polymers/polypeptides 190–197
 - antibacterial mechanism types
 - by 182
 - antimicrobial peptide-based therapy 566–567
 - assembly enrichment 196
 - carbonyl translocation 196
 - chain length and end group 194
 - classes of AMP-mimic polymers/polypeptides 190–191
 - conjugation of 186–190
 - designing of AMP-mimics 191–192
 - hydrophilic residues 194
 - hydrophobic/hydrophilic balance 193
 - natural 179–183
 - physicochemical properties of antibacterial peptide-polymers 196–197
 - positive charge 192–193
 - secondary structure 195
 - side-chain structure 193–194
 - stereochemistry 194–195
 - structural characteristics of AMP-mimic polymers/polypeptides 192–196
 - synthetic 183–185
 - topology 195–196
- antimicrobial peptides integrated Cu²⁺ coordinated polydopamine antibacterial ureteral stents 626
 - antimicrobial study of PDPA@Cu-75-AMP coating 626–627, 627
- antimicrobial photocatalysis
 - applications of 539
 - dentistry applications 542–544
 - environmental applications 539–541
 - mechanisms of microbial damage via photocatalysis 540
 - medical and laboratory applications 541–542
 - ROS role in 538–539
- antimicrobial photodynamic therapy (aPDT) 387
 - categories and applications of biomaterials in 388
- antimicrobial photothermal peptide (AMP) 571
- antimicrobial resistance (AMR) 230, 275

- determinants 235
- factors in antibiotic resistance spread 235
- positive outcomes of 236
- ramifications of 230–234
- in realm of human healing 235–236
- antimicrobial silver nanoparticle-coated MXene (AgNPs/MXene) 358
- antimicrobial sonodynamic therapy (aSDT) 450, 453, 517
- antimicrobial surfaces
 - with active mechanisms 591–596
 - implant-associated infections 587
 - with passive–active integrated mechanisms 596–601
 - with passive mechanisms 588–591
 - smart antimicrobial surfaces 601–607
 - strategies for fabrication of antimicrobial surfaces 588
- antimicrobial therapy
 - NO delivery hydrogel for 377–380, 378
 - NO delivery microneedles for 380–382
 - NO delivery surface coatings for 374–375, 376–377
 - NO delivery systems for 374–382
- antimony trioxide (Sb₂O₃) 533
- anti-scarring therapy 570–571
- aPDT. *see* antimicrobial photodynamic therapy (aPDT)
- AP-MSNs. *see* amino-modified mesoporous silicon nanoparticles (AP-MSNs)
- APS. *see* ammonium persulfate (APS)
- AR88. *see* acid red 88 (AR88)
- arginine (Arg) 192, 403
- arginine–glycine–aspartic acid–cysteine (RGDC) 407, 433
- arsphenamines 233
- artificial intelligence (AI) 522
 - piezoelectric materials application in 522–523
- aSDT. *see* antimicrobial sonodynamic therapy (aSDT)
- atomic force microscopy (AFM) 154, 329
- atom transfer radical polymerization (ATRP) 41, 89, 116
- ATRP. *see* atom transfer radical polymerization (ATRP)
- Avogadro's number 533
- azide-alkyne click chemistry 46
- Azo. *see* azobenzene (Azo)
- azobenzene (Azo) 129
- azoles 233
- b**
- Bacillus megaterium* RRM2 206
- Bacillus mojavensis* A21-derived alkaline proteases 206
- Bacillus safensis* strain PRN1 205
- Bacillus siamensis* CSB55 205
- Bacillus* sp. Mar64 207
- Bacillus subtilis* ZMS-2 protease 207
- Bacillus tequilensis* ZMS-2 206–207
- bacitracin 232
- bacteria 113
- bacteria-killing strategy 85, 114
- bacterial adhesion
 - factors influencing 151
 - roughness effect on 152
 - surface charge effect on 152
 - surface hardness effect on 152
 - surface pattern effect on 151
 - surface wettability effect on 152
- bacterial biofilm eradication, cationic polymers for 68–69
- bacterial cellulose (BC) hydrogel 494
- bacterial infections 481, 531
- bacterial skin infection 553
- bacteria-resisting strategy 85, 114
- bacteria-resisting surfaces 114
- bacteria-responsive antimicrobial surfaces 601–605
- bactericidal agents 161
- bactericidal polymers 116
- bactericidal QAS 606
- “bactericidal to anti-adhesion” surface 100
- bacteriochlorins 389
- band theory 533
- barium titanate (BTO) 457, 490, 495
- BaTiO₃. *see* barium titanate (BTO)
- BaTiO₃ nanotubes (BNT) 490
- BBB. *see* blood-brain barrier (BBB)
- BBR. *see* berberine chloride (BBR)
- benzyl quaternary ammonium salt 4
- berberine chloride (BBR) 403
- berberine-loaded zein nanoparticles coatings as
 - antibacterial ureteral stents 621
 - antibacterial study of ZB stent 622–624, 623
- β-amino acid *N*-thiocarboxyanhydride (β-NTA) 190
- β-amino acid polymers 190
- β-cyclodextrin (β-CD) 125
- β-defensins 180, 181
- β-lactams 560
- BFEE. *see* boron trifluoride ethyl ether (BFEE)
- bifunctional antibacterial surfaces 597, 598. *see also* smart antibacterial surfaces
 - based on “kill and resist” strategy 115–123
 - prepared through co-immobilization/deposition 117–119
 - prepared through co-polymerization 115–117
 - prepared through cross-linking 121
 - prepared through layer-by-layer assembly 121–123
 - prepared through loading 119–121
- bifunctional macromonomer 116
- bimetallic nanoparticles 249–250
- Bi₂MoO₆-poly(ethylene glycol) nanoribbons (BMO NRs) 490, 492

- biocompatibility and safety, piezoelectric materials
 application in 510
- biocompatibility of cationic polymers 69–70
- biodegradable films 594
- biofilm microenvironment (BME) 517
- biofilms 85, 89, 370, 488
 antimicrobials in 558–560
 biofilm-associated infections 531
- biofouling 165
- biogenic silver nanoparticles 243–244
- bioimaging 300–302, 301
- bioinspired surfaces 140
 lotus leaf 140, 141
 mosquito, compound eyes of 141
 organisms 142
 water strider leg 140–141
- biomacromolecules 56
- biomaterials 618
 for antibacterial photodynamic therapy 388
 dressings 405–407
 hydrogels 402–405
 nanomaterials 395–402
 other materials 407–409
 preparation route of Ti-U@SnS₂/I 408
 small-molecule photosensitizers 388–389,
 390–394
- biomedical engineering, applications of MOF-based
 antimicrobial substrates for 264–270
- biomedical industry, protease antibacterial
 materials in 212–213
- bionic bonding method 91
- biophysical studies 184–185
- biosensing 298–300, 299, 554
- bis(hydroxymethyl)propionic acid (bis-MPA) 62
- bismuth 543
- bismuth molybdate (Bi₂MoO₆) 490
- bismuth sodium titanate (BNKT) 494–495
- black phosphorus (BP) 323, 345, 403, 432. *see also*
 violet phosphorus (VP)
 anisotropic properties 348–349
 antimicrobial applications of 349
 electronic and optical properties 348
 liquid-phase exfoliation 347
 mechanical exfoliation 347
 monolayer BP and cell structure 346
 preparation of 347
 properties of 348
 pulsed laser deposition 348
 structure of 345–346
- blood-brain barrier (BBB) 454
- BME. *see* biofilm microenvironment (BME)
- BMO NRs. *see* Bi₂MoO₆-poly(ethylene glycol)
 nanoribbons (BMO NRs)
- BMP-2. *see* bone morphogenetic protein-2 (BMP-2)
- BNKT. *see* bismuth sodium titanate (BNKT)
- BNT. *see* BaTiO₃ nanotubes (BNT)
- bone morphogenetic protein-2 (BMP-2) 437
- boron trifluoride ethyl ether (BFEE) 148
- bottlebrush cationic antimicrobial polymers 59, 60
- bottom-up synthesis methods of
 nanomaterials 282, 283
- bovine antimicrobial peptide-13 182
- bovine serum albumin (BSA) 428, 599–600
- BP. *see* black phosphorus (BP)
- branched cationic antimicrobial polymers 58
 bottlebrush cationic antimicrobial polymers 59
 cationic antimicrobial dendrimers 62
 hyperbranched cationic antimicrobial
 polymers 62–63
 star-shaped cationic antimicrobial
 polymers 59–62
- BSA. *see* bovine serum albumin (BSA)
- BTCA. *see* butane tetracarboxylic acid (BTCA)
- BTO. *see* barium titanate (BTO)
- building construction 167–168
- butane tetracarboxylic acid (BTCA) 214
- butterflies 142
- 1,4-butylene diacrylate 121
- C**
- CA. *see* cellulose acetate (CA); citric acid (CA)
- calcium peroxide (CaO₂) 379
- carbapenems 232
- carbobenzyloxy group (Cbz) 41
- carbon-based 1D antibacterial
 nanomaterials 277–279
 synthesis of 282–285
- carbon-based nanomaterials 395
- carbon-based photothermal materials 428–429
- carbon-based sonosensitizers 457
- carbon dots (CDs) 395
- carbon monoxide (CO) 369
- carbon nanotubes (CNTs) 24, 276, 355, 429
- carbon tetrafluoride (CF) 145
- carbonyl translocation 196
- CarboSil 97
- carboxybetaine (CB) 87
- carboxybetaine monomer (CBOH) 102, 102
- carboxylated graphene modified with ethylene
 glycol chitosan (GCS-CG) 429
- carboxymethyl chitosan (CMCS) 396, 593
- Cassie–Baxter model 143–144
- cathelicidins 180, 181
- catheters, piezoelectric materials used in 504
- cationic antimicrobial dendrimers 62
- cationic antimicrobial polymers 35–36
 cutting-edge applications of 64–70
 design and synthesis of 37–63
 with diverse cationic moieties 46–55
 incorporation strategies for cationic moieties
 into polymers 37–46, 50
 topological structures 56–63
- cationic groups 192
- cationic host defense peptide (CHDP) 184

- cationic liquid (CL) 14
- cationic polymers 1
- classification and features 2–25
 - and current applications in modern medicine, industry, and agriculture 2
 - expanding applications 26
 - guanidinium-based polymers 6–10
 - hybrid systems 21–25
 - imidazolium-based polymers 10–13
 - interdisciplinary integration 25
 - PILs 13–17
 - positively charged dendritic polymers 17–21
 - quaternary ammonium-based polymers 3–6
 - scalability and cost reduction 26
 - sustainability and biodegradability 25
 - targeted and responsive systems 25
- CB. *see* carboxybetaine (CB); conduction band (CB)
- CBOH. *see* carboxybetaine monomer (CBOH)
- Cbz. *see* carbobenzyloxy group (Cbz)
- CDC. *see* US Center for Disease Control and Prevention (CDC)
- CDs. *see* carbon dots (CDs)
- Ce6. *see* chlorin e6 (Ce6)
- cell counting kit-8 (CCK-8) assay 630
- cellulose acetate (CA) 4
- cell walls or membranes, direct damage to 289–290
- central nervous system (CNS) 454
- cephalosporins 233
- CF. *see* carbon tetrafluoride (CF)
- CFUs. *see* colony-forming units (CFUs)
- CHDP. *see* cationic host defense peptide (CHDP)
- chemical bonding method 91
- chemical vapor deposition (CVD) 145–147, 147, 285, 325, 341
- for graphdiyne preparation 335–336
 - for graphene preparation 328
- chemiluminescence (CL) 396
- chemodynamic therapy 424
- chemotherapy-based superhydrophobic antibacterial surfaces 158
- bactericidal agents 161
 - metal-based nanoparticles 158–159
 - N-halamines 160–161
 - quaternary ammonium compounds 159–160
- chitosan (CS) 6, 24, 121, 164, 396, 427, 460
- chitosan-immobilized ficin 212
- chloramphenicol 241, 484
- chlorination 538
- chlorin e6 (Ce6) 162, 397, 456, 517
- chlorins 389
- chlortetracycline 241
- choline sulfate. *see* sulfobetaine (SB)
- chronic skin infections 553
- CI. *see* cochlear implant (CI)
- CIP. *see* ciprofloxacin (CIP)
- ciprofloxacin (CIP) 374, 456, 507, 601, 630
- citric acid (CA) 214
- CL. *see* cationic liquid (CL); chemiluminescence (CL)
- CLEA. *see* cross-linked enzyme aggregates (CLEA)
- click chemistry 46
- clindamycin 562
- clustered repeated interspersed palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) 204
- CMCS. *see* carboxymethyl chitosan (CMCS)
- CNS. *see* central nervous system (CNS)
- CNTs. *see* carbon nanotubes (CNTs)
- coated MNs 557
- coatings, piezoelectric materials used in 507–508
- cochlear implant (CI) 493
- co-immobilization/deposition
- bifunctional antibacterial surfaces prepared through 117–119, 118
 - methods 597
- colony-forming units (CFUs) 455
- co-polymerization 597–598
- bifunctional antibacterial surfaces prepared through 115–117, 115
- combination therapy 565–566
- combined antibacterial and immunomodulatory therapy 569
- combined microacupuncture oxygen and antibacterial therapy 572–574
- condensation reactions 42
- conduction band (CB) 436, 533
- confocal microscopy 51
- conjugation effects 294
- conjugation of AMPs 186, 187
- with antibiotics 186, 188
 - lipidation 186
 - with nanoparticles 188–189, 188
 - with polymers 189–190, 189
- contact-based surface 114
- contact-killing antimicrobial surfaces 591–593, 592
- antimicrobial surfaces with anti-adhesive and 597–599
- contact-killing mechanism 6
- contact potential differences (CPD) 507
- conventional antibacterial MNs 567
- conventional antibacterial therapies 481
- conventional chemotherapy 435
- conventional NO delivery strategies 370
- coordination polymerization 37, 42
- copper nanoparticles (CuNPs) 159
- copper oxide (CuO) 247–248
- copper oxide nanoparticles (CuO NPs) 159
- copper sulfide (CuS) 463
- coprisin 183
- coupling 46
- CPD. *see* contact potential differences (CPD)
- CPFX. *see* ciprofloxacin (CIP)

- CRISPR/Cas9. *see* clustered repeated interspersed palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)
- cross-linked enzyme aggregates (CLEA) 206
- cross-linking, bifunctional antibacterial surfaces prepared through 121, 122
- CS. *see* chitosan (CS)
- curcumin (Cur) 437, 454
- CVD. *see* chemical vapor deposition (CVD)
- cyanine dyes/phthalocyanines 389
- cyclic cationic antimicrobial polymers 57–58, 58
- cyclic di-guanosine monophosphate guanosine (c-di-GMP) 370
- cyclic monomers 41
- cyclic θ -defensins 180, **181**
- cytoserines **231**
- CysHHC10 peptide 189
- cysteine-terminated HHC10 peptide 189
- cytotoxicity 500
- of carbon-based PTMs 428
 - piezoelectric materials application in 510
- d**
- DA. *see* dopamine (DA)
- daptomycin 183
- DCM. *see* dichloromethane (DCM)
- DDS. *see* drug delivery system (DDS)
- deep reactive ion etching (DRIE) 157
- defensins 180
- “defensive” bacteria-resisting surfaces 114
- delivery systems for sonodynamic sterilization materials 458
- liposomes 458–459, 459
 - mesoporous and 2D materials 461–462
 - other delivery methods 462
 - polymer nanoparticles 460–461, 460
- demeclocycline **241**
- dendrimers 62
- dendritic polymers 17, 20–21
- de novo* strategy 192
- dentistry applications, antimicrobial photocatalysis in 542–544
- deoxyribonucleic acid (DNA) synthesis 35, 275
- diabetic wounds. *see also* non-diabetic wounds
- combined microacupuncture oxygen and antibacterial therapy 572–574
 - magneto-thermal therapy 572
 - MNs used to treating infectious 571
 - photothermal therapy 571–572
- diamine compounds 42
- diaminopyrimidines **233**
- diamond-like carbon (DLC) 619
- diarylquinolines **234**
- dichloromethane (DCM) 335
- diffusion-induced interfacial polymerization approach 590
- 4,4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene (BODIPY) 389
- dimethyl-amine oxide (DMAO) 86, **87**
- dimethylalylglycine (DMOG) 408
- dimethyl sulfoxide propionate (DMSP) 86, **87**
- 1,2-dioctadecanoyl-sn-glycero-3-phospho-(1'-racglycerol) (DSPG) 458
- dipole interaction 286
- Dip-Pen Nanolithographic method 542
- Dirac point 329
- direct film formation 149–150
- dissolving MNs 557–558
- DLC. *see* diamond-like carbon (DLC)
- DMAO. *see* dimethyl-amine oxide (DMAO)
- DMOG. *see* dimethylalylglycine (DMOG)
- DMSP. *see* dimethyl sulfoxide propionate (DMSP)
- DNNC. *see* double network nanocomposite hydrogel (DNNC)
- dopamine (DA) 117, 350, 409
- doped semiconductors 534
- doping in photocatalysis 536–537
- double network nanocomposite hydrogel (DNNC) 513
- double-walled carbon nanotubes (DWCNTs) 278
- DOX. *see* doxycycline (DOX)
- doxycycline (DOX) 13, **241**, 565
- dressings, antibacterial photodynamic therapy and 405–407
- DRIE. *see* deep reactive ion etching (DRIE)
- drug delivery 302–304, 303
- drug delivery system (DDS) 449
- DSF. *see* dual-scale structured with fluoroalkylsilane (DSF)
- dual-scale structured with fluoroalkylsilane (DSF) 154
- DWCNTs. *see* double-walled carbon nanotubes (DWCNTs)
- e**
- ECDC. *see* European Centre for Disease Prevention and Control (ECDC)
- ECM. *see* extracellular matrix (ECM)
- eDNA. *see* extracellular DNA (eDNA)
- EF. *see* entomopathogenic fungi (EF)
- efflux pump inhibition 64
- EFSA. *see* European Food Safety Authority (EFSA)
- EG. *see* ethylene glycol (EG)
- ELDT gel 406, 407
- electrical stimulation (ES) 494
- electric arc discharge 282
- electrochemical exfoliation 327
- electrochemical method 147–148, 536
- electroluminescent (EL) materials 406
- electron paramagnetic resonance (EPR) technique 543
- electrophoretic deposition (EPD) 96, 97
- electrospinning 287

- EMA. *see* European Medicines Agency (EMA)
- emodin within nanoliposomes (N-EMO) 458
- endogenous proteases 212
- endogenous stimuli 372
- endopeptidases 212
- endoproteases 204
- endotoxin removal, cationic polymers for 66–68
- endotoxins 36
- energy band depletion 486–487
- energy band theory 486
- engineering semiconductors for visible-light photocatalysis 536–537
- enhanced permeability and retention (EPR) 469
- Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.* (ESKAPE) 195
- entomopathogenic fungi (EF) 243–244
- EPD. *see* electrophoretic deposition (EPD)
- epitaxial growth method 328
- EPR. *see* enhanced permeability and retention (EPR)
- erythromycin sulfisoxazole **241**
- ES. *see* electrical stimulation (ES); external stimulation (ES)
- Escherichia coli* 379
- ESKAPE. *see* *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.* (ESKAPE)
- etching 146
- ethambutol **234**
- ethylene glycol (EG) 286
- European Centre for Disease Prevention and Control (ECDC) 236
- European Food Safety Authority (EFSA) 236
- European Medicines Agency (EMA) 236
- Evaporated Nitrogen Minimum Intensity Layered Delamination (EN-MILD) synthesis method 356
- exogenous stimuli 372
- exoproteases 204
- external stimulation (ES) 350
- extracellular DNA (eDNA) 558
- extracellular matrix (ECM) 402
- extracellular polymeric substance (EPS) matrix 7, 68, 88–89, 139, 213, 275, 370, 454, 558
- f**
- F-MSNs. *see* fluorinated mesoporous silica nanoparticles (F-MSNs)
- FDA. *see* Food and Drug Administration (FDA)
- femtosecond laser-induced periodic surface structures (fs-LIPSSs) 155
- Fenton reaction-enhanced aSDT platform 467
- fiber membrane ureteral stents (FMBUS) 628, 628, 629, 630
- ficin 203–204
- flexible polyurethane with calcined waste eggshell (FPU/CWES) 495
- florfenicol **241**
- fluoridation method 600
- fluorinated mesoporous silica nanoparticles (F-MSNs) 160
- fluorine-free superhydrophobic coating 154
- fluoroquinolone antibiotics (FQs) 456
- fluoroquinolones **233, 241**
- FMBUS. *see* fiber membrane ureteral stents (FMBUS)
- Food and Drug Administration (FDA) 405–406, 461
- food-grade gallate esters 405
- food industry, protease antibacterial materials in 207–212
- FPU/CWES. *see* flexible polyurethane with calcined waste eggshell (FPU/CWES)
- FQs. *see* fluoroquinolone antibiotics (FQs)
- free radical polymerization 37, 42
- fullerenes 395–396
- Fusarium oxysporum* 8
- fusidic acid **232**
- g**
- GA. *see* gelatin (GA)
- gantrisin **241**
- gatifloxacin (GFLX) 456
- GCC. *see* grass carp collagen (GCC)
- GCS. *see* glycol chitosan (GCS)
- GCS-CG. *see* carboxylated graphene modified with ethylene glycol chitosan (GCS-CG)
- GDY. *see* graphdiyne (GDY)
- GDY HHMSs. *see* GDY hierarchical hollow microspheres (GDY HHMSs)
- GDY hierarchical hollow microspheres (GDY HHMSs) 335
- gelatin (GA) 402
- gelatin methacrylamide (GelMA) 403
- gelatin methacrylate (GelMA) hydrogels 267
- gelatin nanoparticles (GNP) 571
- GelMA. *see* gelatin methacrylamide (GelMA)
- gentamicin **241**
- GFLX. *see* gatifloxacin (GFLX)
- GHG. *see* greenhouse gas (GHG)
- global sequence control 56
- glutaraldehyde (GTA) 429, 432
- glutathione (GSH) 292, 492, 574
- Gly-POX20. *see* glycine-pendant poly(2-oxazoline) (Gly-POX20)
- glycidyl methacrylate (GMA) 90
- glycine-pendant poly(2-oxazoline) (Gly-POX20) 196
- glycol chitosan (GCS) 431
- glyco-modified antibacterial polymers 191
- glycopeptides **231**

- GMA. *see* glycidyl methacrylate (GMA)
- GNCs. *see* gold nanoclusters (GNCs)
- GNP. *see* gelatin nanoparticles (GNP)
- GNPL. *see* gold nanoparticle layer (GNPL)
- GO. *see* graphene oxide (GO)
- gold nanocages (AuNCs) 425, 515
- gold nanoclusters (GNCs) 358, 574
- gold nanoparticle layer (GNPL) 130
- gold nanoparticles (AuNPs) 237, 245–246, 462
- gold nanorods (AuNRs) 353, 425
- gold nanostars (AuNSs) 425
- “grafting from” method 89, 590, 599
 construction of zwitterionic antibacterial surface based on 89–90
- “grafting to” method 89, 590
 construction of zwitterionic antibacterial surface based on 90–91, 92
- graft-to method 59
- gram-negative bacteria 70, 71
- gram-positive bacteria 70, 71
- graphdiyne (GDY) 324, 333
 antimicrobial applications of 338–339
 biocompatibility 338
 chemical vapor deposition 335–336
 electrical properties 336
 energy band structure of 337
 interfacial synthesis method 334–335
 optical properties 336–338
 preparation of 334
 properties of 336
 structure of 333, 334
 surface template method 335
- graphene 325, 429
 antibacterial applications of 331–333
 chemical properties 328–329
 chemical vapor deposition 328
 electrical and photoelectrical properties 329–331
 electrochemical exfoliation 327–328
 epitaxial growth method 328
 graphene-based materials 323
 liquid-phase exfoliation 328
 mechanical and thermal properties 329
 mechanical exfoliation 327
 preparation of 327
 properties of 328
 structure of 325, 327, 326
- graphene oxide (GO) 24, 395, 429, 500
 graphene oxide-cationic polymer composites 23
- graphene-related materials (GRMs) 500
- graphite 327
- grass carp collagen (GCC) 24
- greenhouse gas (GHG) 217
- green therapy 369
- GRMs. *see* graphene-related materials (GRMs)
- GSH. *see* glutathione (GSH)
- GTA. *see* glutaraldehyde (GTA)
- guanidinium-based polymers 6, 8
 advantages and limitations 9–10
 agricultural films and coatings 8–9
 applications of 7–9
 chemical structure and mechanism of action 7
 in dental applications 7–8
 recent advances and innovations 9
 wound care and medical devices 7
- guanidinium cations 51–53, 53
- guanidinium groups 9–10
- guanidinium-rich polymer (PG) 467–468
- guar gum (GG) 358
- ## h
- HA. *see* hyaluronic acid (HA)
- halophilic nanoproteases 205–206
- HAMA. *see* methacrylated HA (HAMA)
- HAs. *see* humic acids (HAs)
- H-CDs. *see* hemin-modified CDs (H-CDs)
- HD 6. *see* human α -defensin 6 (HD 6)
- HDPE. *see* high-density polyethylene (HDPE)
- heat shock protein 70 (HSP70) 432
- heat shock proteins (HSPs) 423
- Helicobacter pylori* 471
- hematoporphyrin (HP) 454
- hematoporphyrin monomethyl ether (HMME) 454
- hemin-modified CDs (H-CDs) 396
 preparation of 397
- heterogeneous nucleation 144–145, 144–145
- heterojunctions 537
- HFFs. *see* human foreskin fibroblasts (HFFs)
- high-density polyethylene (HDPE) 149
- highest occupied molecular orbital (HOMO) 423
- histatins 213
- HLopt2 186
- HMME. *see* hematoporphyrin monomethyl ether (HMME)
- hollow MNs 557
- HOMO. *see* highest occupied molecular orbital (HOMO)
- HP. *see* hematoporphyrin (HP)
- HPC. *see* hydroxypropyl cellulose (HPC)
- HSP70. *see* heat shock protein 70 (HSP70)
- HSPs. *see* heat shock proteins (HSPs)
- human α -defensin 6 (HD 6) 183
- human foreskin fibroblasts (HFFs) 630
- humic acids (HAs) 402
- hyaluronic acid (HA) 122, 350, 397, 437, 557
 hyaluronic acid-based responsive NO-releasing MN 381
- hyaluronidase 603
- hybrid inorganic-organic PTMs 421
- hybrid systems 21, 22
 advantages and limitations 24–25
 applications 23–24

- chemical structure and mechanism of
 - action 22–23
 - environmental applications 23–24
 - food packaging 24
 - medical applications 23
 - recent advances and innovations 24
 - hydration mechanism 87
 - hydrochloric acid (HCl) 41
 - hydrogels 10, 377, 402–405
 - membrane 513
 - MNs 558
 - NO delivery hydrogel for antimicrobial therapy 377–380, 378
 - riboflavin-loaded supramolecular hydrogel 403
 - hydrogen fluoride (HF) etching method 355
 - hydrogen peroxide (H₂O₂) 450
 - hydrogen sulfide (H₂S) 369
 - hydrophilic hydrogel coatings 119
 - hydrophilic residues 194
 - hydrophilic surfaces 152
 - hydrophobic/hydrophilic balance 193
 - hydrophobic surfaces 152
 - 2-hydroxyethyl acrylate (HEA) 121
 - 2-hydroxyethyl methacrylate (HEMA) 90
 - hydroxyl radicals (•OH) 450, 538–539
 - hydroxypropyl cellulose (HPC) 557
 - hyperbranched cationic antimicrobial polymers 62–63, 63
 - hyperbranched polyamideamine with silver-gold NPs (HBPAAs Ag@Au NPs) 627
 - antibacterial activity 628–630
- i**
- IAIs. *see* implant-associated infections (IAIs)
 - ICG. *see* indocyanine green (ICG)
 - IL. *see* ionic liquid (IL)
 - imidazolium-based polymers 10
 - advantages and limitations 13
 - applications 10–12, 11
 - chemical structure and mechanism of action 10
 - environmental and industrial applications 12
 - food packaging 12
 - medical applications 10–12
 - recent advances and innovations 12–13
 - immunotherapy 424, 435
 - synergistic photothermal-immunotherapy 438–440
 - implantable devices, piezoelectric materials
 - application in 512–515
 - implant-associated infections (IAIs) 587
 - implant infection, sonodynamic sterilization materials for 465–466
 - implants, piezoelectric materials used in 504
 - indocyanine green (ICG) 396, 430, 454, 559–560
 - infected oral diseases, sonodynamic sterilization materials for 466–467
 - infective myositis 469
 - innate defense regulator (IDR) peptides 185
 - inorganic–organic hybrid PTMs 433
 - inorganic PTMs 421
 - inorganic sonosensitizers 456–457
 - in situ* generation of cationic groups during polymerization 42–46, 43–45
 - intact skin 553
 - interface functionalization strategy 439
 - interfacial synthesis method 334
 - interstitial fluid (ISF) 557
 - intracellular components, destruction of 291
 - invertebrate AMP 180
 - ion conduction 286
 - ionic liquid (IL) 13
 - ion insertion exfoliating method 341
 - IONPs. *see* iron oxide nanoparticles (IONPs)
 - iron oxide 249
 - iron oxide nanoparticles (IONPs) 249
 - irreversible thermal injury 424
 - ISF. *see* interstitial fluid (ISF)
- k**
- kanamycin 241
 - keratinolytic proteases 205
 - “kill and release” antibacterial strategies 114
 - smart antibacterial surfaces based on 123–132
 - “kill and resist” antibacterial strategies 114
 - bifunctional antibacterial surfaces based on 115–123
- l**
- LA. *see* lactic acid (LA)
 - lactic acid (LA) 624
 - Langmuir–Blodgett coating technology (LB coating technology) 564
 - L-Arg. *see* L-arginine (L-Arg)
 - L-arginine (L-Arg) 408, 560
 - laser ablation 282–285
 - layer-by-layer (LBL) assembly 93, 98, 121, 597
 - bifunctional antibacterial surfaces prepared through 121–123, 122
 - deposition 148, 148
 - layered material. *see* two-dimensional material (2D material)
 - LB coating technology. *see* Langmuir–Blodgett coating technology (LB coating technology)
 - LBP. *see* lipopolysaccharide-binding protein (LBP)
 - LCST. *see* lower critical solution temperature (LCST)
 - LDPE. *see* low-density polyethylene (LDPE)
 - lead magnesium niobate-lead titanate (PMN-PT) 498
 - lead zirconate titanate (PZT) 489–490
 - leather and detergent industry, protease antibacterial materials in 205–207, 207
 - levofloxacin (LVFX) 186, 456

- light-induced antibacterial 293–296, 294, 295
 light-induced hyperthermia 436
 light-responsive technologies 531
 light responsivity, smart antibacterial surfaces
 with 129–130, 129
 lincosamides 231
 lipiarmycins 232
 lipidation 186
 lipopeptides 232
 lipopolysaccharide-binding protein (LBP) 66
 lipopolysaccharides (LPSs) 64, 66, 564
 neutralization 66–67
 promotion of LPS aggregation 67
 liposomes 458–459
 liquid-phase exfoliation (LPE) 327–328, 341
 for black phosphorus 347
 lithium niobate (LiNbO₃) 493
 LL-37 peptide 180
 loading, bifunctional antibacterial surfaces
 prepared through 119–121, 120
 localized surface plasmon resonance (LSPR) 335,
 422
 local sequence control 56–57
 lotus leaf 140, 141
 low-density polyethylene (LDPE) 145
 lower critical solution temperature (LCST) 123
 lowest unoccupied molecular orbital (LUMO) 423
 LPE. *see* liquid-phase exfoliation (LPE)
 LPSs. *see* lipopolysaccharides (LPSs)
 LSPR. *see* localized surface plasmon resonance
 (LSPR)
 LUMO. *see* lowest unoccupied molecular orbital
 (LUMO)
 lung infection, sonodynamic sterilization materials
 for 470
 luteolin (Le) 381
 LVFX. *see* levofloxacin (LVFX)
 lysine 192
 lysozyme 161, 179
 lysozyme-functionalized polyurethane 407
- m**
 macrolides 231
 macromonomer polymerization 59
 magainin 186
 magnesium oxide (MgO) 248
 magnetic resonance imaging (MRI) 453
 magnetothermal therapy 452, 572
 magnetron sputtering technique 536
 maltohexaose 458
 MAMs. *see* mechanically assembled monolayers
 (MAMs)
 MAPC. *see* multifunctional nanoplatform (MAPC)
 marine shipping 165–167
 matrix metalloproteinases (MMPs) 204
 MB. *see* methylene blue (MB); microbubble (MB)
 MBC. *see* minimum bactericidal concentration
 (MBC)
 mechanical exfoliation 327
 for black phosphorus 347
 for violet phosphorus 352
 mechanically assembled monolayers
 (MAMs) 149
 mechanical therapy sterilization 155–158, 158
 medical and health industry 163–165, 165, 166
 membrane disruption 64
 membrane translocation 64
 MEMS. *see* microelectrical mechanical system
 (MEMS)
 mesenchymal stem cell (MSC) 495
 mesoporous and 2D materials 461–462
 mesoporous gold (MP-Au) thin films 515
 meso-tetrakis(4-sulfonatophenyl) porphyrin
 (TPPS@Au) 463
 metal
 combination of PDT and 565–566
 doping 537
 ion leaching 292–293
 metal-based sonosensitizers 457
 metal-based therapy 563–564, 567–568
 metal-free photocatalysts 533
 nanoparticles 158–159, 395, 422, 600
 metal-based 1D antibacterial
 nanomaterials 279–281
 synthesis of 285–287
 metallothionein (Mt) 465
 metal-organic frameworks (MOFs) 263, 264, 382,
 396
 biomedical engineering, MOF-based
 antimicrobial substrates for 264–270
 MOF-based 3D-printed substrates 269,
 271, 272
 MOF-based drug delivery carrier 267–269, 268,
 269
 tissue regeneration, MOF-based antimicrobial
 substrates for 267
 wound dressing, MOF-based antimicrobial
 substrates for 265–267
 metal oxides 456
 metal-phenolic networks (MPNs) 117
 (meth)acrylamides 37
 methacrylated HA (HAMA) 558
 (meth)acrylates 37
 [2-(methacryloyloxy) ethyl] dimethyl-
 (3-sulfopropyl) ammonium hydroxide
 (SBMA) 90
 (2-(methacryloyloxy) ethyl)-4-methyl-2-
 oxo-morpholinium trifluoroacetate
 (MMQAS) 103
 2-methacryloyloxyethyltrimethylammonium
 chloride (METAC) 90, 116
 methicillin resistant *Staphylococcus aureus*
 (MRSA) 113, 230, 234, 339, 397, 426, 455,
 485, 561
 methoxypoly(ethylene glycol)-block poly(l-lactide-
 co-ε-caprolactone) (mPEG-PLCL) 619

- methylene blue (MB) 430
 methylene blue-loaded PLGA nanoparticles (PLGA-MB) 461
 MF. *see* microfiltration (MF)
 MHB. *see* Mueller–Hinton broth (MHB)
 MIC. *see* minimum inhibitory concentrations (MIC)
 microbial aggregates 88–89
 microbial menace 227–229
 microbubble (MB) 450
 MB-Pip 454
 types of 454
 microdialysis 560
 microelectrical mechanical system (MEMS) 555
 microfiltration (MF) 493
 microfluidic spinning 288
 microgrooves 151
 micro/nanoparticles, piezoelectric materials used in 507–508
 microneedles (MN) 380, 554
 advantages in managing skin infections 558–561
 application of 554–555
 characteristics of 556
 classification 556, 556
 coated MNs 557
 combination therapy 565–566
 development of 555–556, 555
 dissolving MNs 557–558
 drug therapy 561–562
 hollow MNs 557
 hydrogel MNs 558
 metal-based therapy 563–564
 MNs used to treating infectious diabetic wounds 571–574
 NO delivery microneedles for antimicrobial therapy 380–382
 photodynamic therapy 562–563
 polyionic liquid-based therapy 564–565
 solid MNs 556
 sonodynamic therapy 563
 theranostic MNs 574–577
 treatment of wound infections 381
 used for managing skin infections 554
 used to treating infectious non-diabetic wounds 566–571
 used to treating skin infections without wounds 561
 micropores 151
 microprotrusions 151
 microwave-assisted synthesis 286
 milk-clotting enzymes 212
 minimum bactericidal concentration (MBC) 51
 minimum inhibitory concentrations (MIC) 183, 242, 453
 MMPs. *see* matrix metalloproteinases (MMPs)
 MN. *see* microneedles (MN)
 MOFs. *see* metal-organic frameworks (MOFs)
 monobactams 232
 monoclinic scheelite bismuth vanadate (m-BVO) piezo-photocatalyst 492
 Morse code 496
 mosquito, compound eyes of 141
 MPNs. *see* metal–phenolic networks (MPNs)
 MRI. *see* magnetic resonance imaging (MRI)
 MRSA. *see* methicillin resistant *Staphylococcus aureus* (MRSA)
 MSC. *see* mesenchymal stem cell (MSC)
 mucositis 542
 Mueller–Hinton broth (MHB) 622–623
 multidrug-resistant (MDR) bacteria 113, 481, 531
 of dangerous pathogenic bacteria 387
 multifunctional nanoplatform (MAPC) 517
 multifunctional photocatalytic coatings 546
 multifunctional piezoelectric elastomer 485
 multi-walled carbon nanotubes (MWCNTs) 278
 mupirocin 232
 MWCNTs. *see* multi-walled carbon nanotubes (MWCNTs)
 MXenes 353
 alkali etching 356
 antimicrobial applications of 358–360
 electrical properties 356
 electrochemical etching 355
 HF etching 355
 mechanical property 357–358
 MXene-decorated nanofibrous membrane 406
 optical performance 356–357
 preparation of 355
 properties of 356
 structure of 354–355, 354
Mycobacterium smegmatis 456
 myositis, sonodynamic sterilization materials for 469
- n**
- nalidixic acid 241
 nanocarrier-based delivery systems 65
 nanocomposite (NC) 498
 nanogenerators 512, 515
 nanomaterials 276, 395
 antimicrobial nanoplatforms as carriers 398–400
 as PSs 395–396
 PSs loaded on nanomaterial-based carriers 396–397, 401–402
 nanomicelle-encapsulated curcumin (NM@Cur) 467
 nanoparticles (NPs) 186, 237, 395, 484
 action mechanisms 238–239, 238
 antimicrobial substances 238
 conjugation of AMPs with 188–189, 188
 nanophotosensitizers (NPSs) 395
 nanoripples 151
 nanoscale graphene 327

- nanosensitizers 453
- nanostuctures with high aspect ratios 151
- nanotechnology 236, 276
- nanoparticle action mechanisms 238–239, 238
 - nanoparticles containing antimicrobial substances 238
 - resources 237
- nano TiO₂ (NTO) 214
- nanotubes 151
- nanozyme antibacterial therapy 570
- natural AMPs, 179. *see also* synthetic AMPs
- antibacterial activity 180–182
 - antifungal activity 183
 - antiviral activity 182
 - applications of 183
 - types of 180, **181**
- natural polymers 396
- natural polysaccharides 557
- natural proteins 557
- natural zwitterions 86
- NC. *see* nanocomposite (NC)
- NCAs. *see* N-carboxyanhydrides (NCAs)
- N-carboxyanhydrides (NCAs) 41, 190
- N-diazeniumdiolate (NONOate) 372, 373
- near-infrared (NIR) 161, 331, 422, 456
- irradiation 125
 - laser irradiation 379
- N-EMO. *see* emodin within nanoliposomes (N-EMO)
- neutralization
- cationic polymers for 66–68, 67
 - of LPS 66–67
- neutral proteases 204, 211
- N-halamines 160–161
- N-hydroxyethylacrylamide (HEAA) 115–116
- N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer 189
- NIR. *see* near-infrared (NIR)
- N-isopropylacrylamide (NIPAAm) 606
- nitric oxide (NO) 92, 248, 369
- antimicrobial mechanism of 370–371, 371
 - delivery systems for antimicrobial therapy 374–382
 - donor and responsive release 371–373, 373
 - traditional gas administration strategies 369–370
- nitrofurans **233**
- N-methylpyridinium ions 41
- noble metal-based photothermal materials 425–427
- non-diabetic wounds. *see also* diabetic wounds
- antibacterial and anti-scarring therapy 570–571
 - antimicrobial peptide-based therapy 566–567
 - combination therapy 569
 - combined antibacterial and immunomodulatory therapy 569
 - metal-based therapy 567–568
 - MNs used to treating infectious 566
 - nanozyme antibacterial therapy 570
 - ultrasound activated therapy 568–569
- non-ionic hydrophilic polymers 85
- nonmetal doping 537
- nonmetallic inorganic materials 457
- non-radiative relaxation 294
- non-template method 286–287
- norbornene monomers 41–42
- NPs. *see* nanoparticles (NPs)
- NPSs. *see* nanophotosensitizers (NPSs)
- n-type semiconductors 534
- nucleic acids 56
- O**
- OASM. *see* oriented antibacterial sericin microneedle (OASM)
- 4-octyl itaconate (4OI) 403
- synthesis of 4OI–BP@Gel 404
- OD. *see* optical density (OD)
- “offensive” bacteria-resisting surfaces 114
- oligo (ethylene glycol) (OEG) 70
- OMCN. *see* oxidized mesoporous carbon nanoparticles (OMCN)
- omigaganan 184
- one-dimensional (1D) antibacterial nanomaterials 276, 277, 278
- advantages and disadvantages of main preparation methods for **284**
 - biomedical applications 298–306
 - carbon-based 1D antibacterial nanomaterials 277–279
 - future perspectives 306–307
 - metal-based 1D antibacterial nanomaterials 279–281
 - 1D antibacterial nanofibrous materials 281, 287–289
 - physicochemical antimicrobial mechanisms of 289–298, 290
 - synthesis 282–289
- “one-step” copolymerization 116
- OP. *see* oxygen permeability (OP)
- OPN. *see* osteopontin (OPN)
- optical density (OD) 623
- organic bactericides 594–595
- organic-modified silica gels 167
- organic photothermal materials 421, 429–432
- PLNP@PANI-GCS as PTMs for antibacterial PTT 432
- organic small molecule-based PTMs 430, 431
- organic sonosensitizers 454–456
- chemical structures of 455
- oriented antibacterial sericin microneedle (OASM) 567, 568
- oriented sericin microneedle (OSM) 568

- OSM. *see* oriented sericin microneedle (OSM)
- osteogenesis 468
- osteomyelitis, sonodynamic sterilization materials for 467–469
- osteopontin (OPN) 299
- oxazolidinones 234
- oxazoline-based cationic polymers 51
- OXD. *see* oxidase (OXD)
- oxidase (OXD) 570
- oxidative stress 291–292
- oxidized mesoporous carbon nanoparticles (OMCN) 379
- oxygen permeability (OP) 24
- oxytetracycline 241
- ozonation 538
- P**
- palladium (Pd) 426
- palygorskite (Pal) 600
- PANI. *see* polyaniline (PANI)
- PASs. *see* polyamidosaccharides (PASs)
- passive–active integrated mechanisms. *see also* active mechanisms
- anti-adhesive and contact-killing mechanisms 597–599
 - anti-adhesive and release-killing mechanisms 599–601
 - antimicrobial surfaces with 596
- “passive defense” antibacterial strategy 92, 596
- passive mechanisms, antimicrobial surfaces with 588–591
- pathogenic bacteria 113
- pathogenic microorganisms 370
- PBA. *see* phenylboronic acid (PBA)
- PBAM. *see* phenylboronic acid and acryloylmorpholine copolymer (PBAM)
- PBS. *see* phosphate buffered saline (PBS)
- PC. *see* phosphorylcholine (PC)
- PCB. *see* printed circuit board (PCB)
- PCL. *see* polycaprolactone (PCL)
- PCN-224. *see* porous coordination network-224 (PCN-224)
- PCT. *see* photocatalytic therapy (PCT)
- PDA. *see* polydopamine (PDA)
- PDMS. *see* polydimethylsiloxane (PDMS)
- PDT/PCT. *see* photodynamic/photocatalytic therapy (PDT/PCT)
- PE. *see* polyester (PE)
- PEG. *see* polyethylene glycol (PEG)
- PEI. *see* polyethyleneimine (PEI)
- penicillins 232
- peptide-mimicking polymers 191
- peptoid polymers 191
- perfluorohexane (PFH) 396
- periodontitis 467
- peroxidase (POD) 570
- perylene tetracarboxylate (PTCA) 328
- PET. *see* polyethylene terephthalate (PET)
- pexiganan 184
- PFH. *see* perfluorohexane (PFH)
- PHA. *see* polydopamine-modified hydroxyapatite (PHA)
- phase-transitioned lysozyme film (PTLF) 130–131
- PHB. *see* polyhydroxybutyrate (PHB)
- phenazines 234
- phenicols 241
- phenol soluble modulins (PSMs) 213
- phenothiazines 389
- phenylboronic acid (PBA) 131
- phenylboronic acid and acryloylmorpholine copolymer (PBAM) 374
- phenylboronic acid grafted with sodium alginate (Alg-PBA) 358
- 2-phenylethynyl sulfonamide (PES) 432
- PHMB. *see* polyhexamethylene biguanide (PHMB)
- phosphate buffered saline (PBS) 560
- phospholipase A2 (PLA2) 458
- phosphonates 231
- phosphonium-based cations 53–54
- phosphorene 347
- phosphorus-based semiconductors 433
- phosphorylcholine (PC) 87
- photoacoustic (PA) signal 458
- photocatalysis 531–532
- applications of antimicrobial photocatalysis 539–544
 - background and progress in 532–533
 - engineering semiconductors for visible-light photocatalysis 536–537
 - fundamentals of 533–535, 534
 - photocatalytic mechanisms in TiO₂ interfaces 535
 - ROS role in antimicrobial photocatalysis 538–539
 - synthesis of photocatalysts targeting biomedical applications 544–546
 - UV-responsive TiO₂ surfaces 535–536
- photocatalyst–bacteria interactions 539
- photocatalysts targeting biomedical applications, synthesis of 544–546, 545
- photocatalytic coatings 532
- photocatalytic decontamination 541
- photocatalytic self-cleaning materials 541
- photocatalytic therapy (PCT) 428
- photodynamic/photocatalytic therapy (PDT/PCT) 435
- synergistic photothermal-photodynamic/photocatalytic therapy 436–437
- photodynamic therapy (PDT) agents 5–6, 162–163, 162, 342, 396, 424, 449, 515, 562–563
- photoelectrochemical sterilization of *Saccharomyces cerevisiae* 538

- photosensitizers (PSS) 387, 436
 loaded on nanomaterial-based carriers 396–402
 nanomaterials as 395–396
 small-molecule 388–389, 390–394
 phototherapy-based superhydrophobic
 antibacterial surfaces 161
 photodynamic therapy 162–163, 162
 photothermal therapy 163, 164
 photothermal agents (PTAs) 163, 422
 photothermal antibacterial therapy 565
 photothermal-based synergetic therapy 433
 PTMs for antibacterial PTT 434
 synergistic photothermal
 chemotherapy 435–436
 synergistic
 photothermal-immunotherapy 438–440
 synergistic photothermal-photodynamic/
 photocatalytic therapy 436–437
 synergistic photothermal-sonodynamic
 therapy 438
 therapeutic modalities combined with PTT 435
 photothermal conversion 293–294
 photothermal materials (PTMs) 421, 422–423
 mechanisms underlying the photothermal
 effect 422
 transition metal-based photothermal
 materials 427–428
 types of 421
 photothermal therapy (PTT) 163, 164, 280, 331,
 379, 396, 421, 452, 515, 565
 agents 9
 for diabetic wounds 571–572
 pH responsiveness, smart antibacterial surfaces
 with 125–127, 126, 127
 physical adsorption method 91
 physical vapor deposition (PVD) 341
 piezocatalytic antibacterial therapy 481–482
 piezoelectric catalysis 486
 piezoelectric ceramics 489–493
 piezoelectric effect 486
 piezoelectric-enhanced sonosensitizer 485
 piezoelectric materials 481–482
 antibacterial agents 508–510
 in antibacterial therapy 486
 for antibacterial treatment 483
 applications and strategies 501
 artificial intelligence technology 522–523
 background of antibacterial therapy 484–485
 for bacterial degradation 483
 biocompatibility and safety 510–512
 challenges and future perspectives 512
 energy band depletion 486–487
 implantable devices 512–515
 mechanism of action 486
 medical devices 501–507
 micro/nanoparticles or coatings 507–508
 multimodal approaches 515, 516
 overview of 489–501
 piezocatalytic bacterial degradation 487
 screening charge effect 487–489
 targeted drug delivery 516–519
 types of 489
 wireless technology 519–520, 521
 piezoelectric polymers 493–496
 piezo-responsive polymeric nanocomposites 496
 flexible ultrasonic device with labeled key
 components 498–499
 mechanical attributes of piezoelectric
 materials 500–501
 organic biomaterials 496, 498
 piezoelectric materials and piezo-responsive
 properties 501
 piezotherapy 482
 mechanical debridement of 484
 piperacillin (Pip) 470
 piperacillin-loaded catalytic MBs (MB-Pip) 470
 PLA. *see* polylactic acid (PLA)
 PLA2. *see* phospholipase A2 (PLA2)
 plasma electrolytic oxidation (PEO) 543
 plasma processing 145
 PLD. *see* pulsed laser deposition (PLD)
 pleuromutilins 233
 PLGA. *see* polylactic acid–glycolic acid copolymer
 (PLGA)
 PMAA. *see* polymethacrylic acid (PMAA)
 POD. *see* peroxidase (POD)
 PolarisTM ultra soft and firm ureteral stent 617,
 618
 polyacrylamides 57
 poly(amidoamine) dendrimer (PAMAM) 18, 62,
 122
 polyamidosaccharides (PASs) 191
 polyaniline (PANI) 430
 polycaprolactone (PCL) 349, 405–406, 576, 618
 poly(carbosilane) (PCS) 62
 poly(carboxybetainemethacrylate) (PCBMA) 590
 poly(cationic liquid)s (PCLs) 14, 14–15
 poly(CBOH) 102
 poly(dimethylaminoethyl methacrylate)
 (polyDMAEMA) 130
 polydimethylsiloxane (PDMS) 116, 149, 347
 poly(3-dimethyl(4-vinylbenzyl)ammoniumpropane
 1-sulfonate) (polyDVBAPS) 128
 polydopamine (PDA) 396, 430, 558
 polydopamine-modified hydroxyapatite
 (PHA) 495
 polydopamine nanoparticles (PDA NPs) 159
 PolyDVBAPS-ITO. *see* polymerized 3-(dimethyl
 (4-vinylbenzyl) ammonium) propyl sulfonate
 onto indium tin oxides (PolyDVBAPS-ITO)
 polyester (PE) 62
 poly(3,4-ethylenedioxythiophene) (PEDOT) 430
 polyethylene glycol (PEG) 85–87, 116, 191, 426,
 453, 590

- poly(ethylene glycol diacrylate) (PEGDA) 429, 563
- poly(ethylene glycol) methyl ether methacrylate (PEGMA) 121
- polyethyleneimine (PEI) 9, 63
- polyethylene terephthalate (PET) 94, 145
- poly(1-ethyl-3-vinylimidazolium furan-2-carboxylate) (PCLs) 15
- poly(γ -glutamic acid) 405
- poly(glycidyl methacrylate) (PGMA) 16
- polyhedral oligomeric silsesquioxanes (POSS) 60, 160
- polyhexamethylene biguanide (PHMB) 93, 116
- poly(hexamethylene guanidine) (polyHMG) 116
- poly(hexamethylene guanidine) hydrochloride 7
- polyhydroxybutyrate (PHB) 517
- poly(3-hydroxybutyric acid-co-3-hydrovaleric acid) (PHBV) 495
- poly(2-hydroxyethyl methacrylate-co-glycidyl methacrylate) (PHG) 90, 91
- polyimidazolium 51
- polyimide (PI) 495–496
- polyionenes 42
- poly(ionic liquid)s (PILs) 13, 554
 - advantages and limitations 17
 - applications 15–17
 - chemical structure and mechanism of action 14
 - food packaging 16–17
 - marine and industrial applications 16
 - medical applications 15–16
 - polyionic liquid-based therapy 564–565
 - recent advances and innovations 17
 - water and wastewater treatment 16
- polylactic acid (PLA) 405, 618
- polylactic acid–glycolic acid copolymer (PLGA) 557
- poly(lactic-co-glycolic acid) (PLGA) 405, 461
- poly(L-lactic acid) (PLLAs) 494
- poly(L-lactide-co-5-amino-1,3-dioxan-2-one) (P(LA-co-AC)) 624–625, 625
 - assessment of antibacterial performance of ureteral stents 625
- poly(L-lactide-co- ϵ -caprolactone) (PLCL) 618
 - antibacterial activity of PLCL5050-CIP stents 631–632, 631
 - copolymers stent 624–625
 - loaded ciprofloxacin stents 630
 - polymeric-modified antibacterial stents **632**
- poly(L-lysine)-*graft*-poly(ethylene glycol) (PLL-g-PEG) 590
- polylysine 405
- polymer-based antibacterial ureteral stents 617
 - performances of polymers modified antibacterial ureteral stents 621–632
 - ureteral stenting procedure 620–621, 621
- polymerization process 599
- polymerized 3-(dimethyl (4-vinylbenzyl) ammonium) propyl sulfonate onto indium tin oxides (PolyDVBAPS-ITO) 99
- polymerized ionic liquids. *see* poly(ionic liquid)s (PILs)
- polymer-peptide-porphyrin conjugate (PPPC) 453
- polymers 85
 - conjugation of AMPs with 189–190, 189
 - nanoparticles 459–461
- polymethacrylic acid (PMAA) 100, 606
- poly(methacrylate sulfobetaine) (PSBMA) 90
- poly(methacrylic acid) (poly-MAA) 125
- poly(2-methacryloyloxyethyl phosphorylcholine) (polyMPC) 90, 117, 590
- poly(methyl methacrylate) (PMMA) 149, 513
- polymyxins **232**
 - B and E 36
 - polymyxin-based drugs 36
- poly(N-isopropylacrylamide) (PNIPAM) 123–124, 429
- polyol method 286
- poly(2-oxazoline)s 191, 196
- poly(pentafluorophenyl acrylate) (polyPFPA) 119
- polypeptides **232**
- poly(p-phenylene vinylenes) (PPVs) 69
- polypropylene (PP) 149
- polypropylene nonwoven fabric membrane (PP NWF) 100
- poly(propylenimine) (PPI) 62
- polypyrrole (PPy) 430, 520
- polypyrrole-graphene oxide (PPy-GO) 333
- polysaccharides 405
- poly(sulfobetaine-3,4-ethylenedioxythiophene) (polyEDOT) 130
- poly(sulfobetaine methacrylate) (PSBMA) 93, 116, 590
- poly(sulfobetaine vinyl imidazole) (pSBVI) 607
- polytetrafluoroethylene (PTFE) 20, 149
- poly((trimethylamine)ethylmethacrylate chloride) (pTMAEMA) 607
- polytrimethylene carbonate (PTMC) 618
- polyunsaturated phospholipids 538
- poly(ureaformaldehyde) nanoparticles (PUF NPs) 160
- polyurethane (PU) 23, 164, 407, 426, 593
- polyvinyl alcohol (PVA) 427, 520, 557
- poly(vinylidene) fluoride (PVDF) 163, 405, 493–494
- polyvinylpyrrolidone (PVP) 557, 603, 619
- porous coordination network-224 (PCN-224) 403
- porphyrins 389
 - derivatives 454
- porphyrin-based hollow metal–organic framework 485
- positively charged dendritic polymers 17, 18–19
 - advantages and limitations 21
 - applications 19–20

positively charged dendritic polymers (*Cont.*)
 chemical structure and mechanism of action 18
 drug delivery systems 20
 environmental applications 20
 medical applications 19–20
 recent advances and innovations 20–21
 POSS. *see* polyhedral oligomeric silsesquioxanes (POSS)
 post-modification for synthesis of cationic polymers 46, **47–49**
 post-zwitterion ionization method 89
 PpIX. *see* protoporphyrin IX (PpIX)
 PPPC. *see* polymer-peptide-porphyrin conjugate (PPPC)
 pre-designed cationic monomers, polymer synthesis based on 37–42
 primary antibacterial strategies 114
 primary self-cleaning strategy 606–607
 printed circuit board (PCB) 498
 prontosil **241**
 protease antibacterial materials 203
 antibacterial protease uses and mechanisms in industries **208–210, 213**
 in biomedical industry 212–213
 challenges and limitations 214–217, 215
 in food industry 207–212
 future perspectives 218
 immobilization/encapsulation of biocatalytic protease used in industries **216–217**
 in leather and detergent industry 205–207, 207 and potential applications 205–214
 in textile industry 213–214
 protegrin 184
 proteins 35, 56
 protoporphyrin IX (PpIX) 454
 Prussian blue nanoparticles 430, 431
 pseudoaggregates, formation of 67
 PSs. *see* photosensitizers (PSs)
 PSMs. *see* phenol soluble modulins (PSMs)
 PTAs. *see* photothermal agents (PTAs)
 PTCA. *see* perylene tetracarboxylate (PTCA)
 PTFE. *see* polytetrafluoroethylene (PTFE)
 PTLF. *see* phase-transitioned lysozyme film (PTLF)
 PTMC. *see* polytrimethylene carbonate (PTMC)
 PTMs. *see* photothermal materials (PTMs)
 PTT. *see* photothermal therapy (PTT)
 PU. *see* polyurethane (PU)
 p-type semiconductors 534, 535
 pulsed laser deposition (PLD) 347
 for black phosphorus 348
 PVA. *see* polyvinyl alcohol (PVA)
 PVD. *see* physical vapor deposition (PVD)
 PVP. *see* polyvinylpyrrolidone (PVP)
 pyridinamides **233**
 pyrolysis 452
 PZT. *see* lead zirconate titanate (PZT)

q

QACs. *see* quaternary ammonium compounds (QACs)
 QAS. *see* quaternary ammonium salts (QAS)
 QCA-X membrane 4–5
 Q-MSNs. *see* quaternary ammonium-functionalized mesoporous silica nanoparticles (Q-MSNs)
 QSI. *see* quorum sensing inhibitor (QSI)
 quaternary ammonium-based polymers 3
 advantages and limitations of 6
 applications of 3–5
 cell membrane destruction by 4
 chemical structure and mechanism of action 3
 food packaging and textiles 5
 medical devices and healthcare 3–4
 recent advances and innovations of 5–6
 water treatment 4–5
 quaternary ammonium compounds (QACs) 159–160
 quaternary ammonium-functionalized mesoporous silica nanoparticles (Q-MSNs) 160
 quaternary ammonium salts (QAS) 159, 602
 quaternized chitosan 6
 quinolones **241**
 quorum sensing inhibitor (QSI) 68

r

radiofrequency (RF) 520
 Radziszewski reaction 42, 46
 RAFT. *see* reversible addition-fragmentation chain transfer polymerization (RAFT)
 random copolymers 94
 rat critical-sized cranial defect model 495
 RB. *see* Rose Bengal (RB)
 RBC. *see* red blood cell (RBC)
 rBPI21 peptide 67
 reactive nitrogen species (RNS) 506
 reactive oxygen intermediates 370
 reactive oxygen species (ROS) 5, 51, 161–162, 239, 265, 279, 324, 435, 436, 450, 482, 562, 596
 production induced by PDT and PCT 437
 role in antimicrobial photocatalysis 538–539
 ROS-based therapies 114
 red blood cell (RBC) 468
 red phosphorus (RP) 347, 432
 reduced graphene oxide (rGO) 355, 429
 release-based surfaces 114
 release-killing antimicrobial surfaces 593–596, **595**
 antimicrobial surfaces with anti-adhesive and 599–601
 retrocyclins 184
 reversible addition-fragmentation chain transfer polymerization (RAFT) 41, 89, 374
 reversible switching between anti-adhesive and bactericidal properties 605–606

- RF. *see* radiofrequency (RF)
 rGO. *see* reduced graphene oxide (rGO)
 RhB. *see* rhodamine B (RhB)
 rhodamine B (RhB) 492
 rhodium (Rh) 42
 riboflavin-loaded supramolecular hydrogel 402, 403
 ribonucleic acid (RNA) 280
 ring-opening metathesis polymerization (ROMP) 37, 41–42
 ring-opening polymerization (ROP) 37, 41
 RNA. *see* ribonucleic acid (RNA)
 RNS. *see* reactive nitrogen species (RNS)
 ROMP. *see* ring-opening metathesis polymerization (ROMP)
 RONOZYME ProAct 210
 ROP. *see* ring-opening polymerization (ROP)
 ROS. *see* reactive oxygen species (ROS)
 Rose Bengal (RB) 406, 454
 RP. *see* red phosphorus (RP)
 ruthenium (Ru) 426
- S**
Saccharomyces cerevisiae, photoelectrochemical sterilization of 538
 salicylates 233
 salicylic acid (SA)-loaded PIL MNs (SA-PIL-MNs) 564–565
 salt responsivity, smart antibacterial surfaces with 127–129, 128
 SA-PIL-MNs. *see* salicylic acid (SA)-loaded PIL MNs (SA-PIL-MNs)
 SB. *see* sulfobetaine (SB)
 SBEDOT. *see* sulfobetaine-3,4-ethylenedioxythiophene (SBEDOT)
 scanning electron microscopy (SEM) 140
 SCD. *see* sulfobutyl ether- β -cyclodextrin (SCD)
 Schottky junctions 537
 screening charge effect 487–489
 SDT. *see* sonodynamic therapy (SDT)
 second-generation FQs 456
 selectivity of cationic polymers 69–70
 selenium (Se) 409
 selenium oxide 249
 selenonium-based cations 55
 self-assembly method 149
 self-cleaning function, smart antimicrobial surface with 606–607
 self-supporting smart air filter (SSSAF) 498
 SEM. *see* scanning electron microscopy (SEM)
 semiconductors 534–535
 semi-inter penetrate network hydrogels (semi-IPN) 15–16
 sensorineural hearing loss (SNHL) 493
 sequence control in cationic antimicrobial polymers 56, 56
 sequence-controlled polymers 36
 sequence-defined cationic antimicrobial polymers 56–57
 sericin MNs (SM) 567
Serratia marcescens PPB-26 207
 SERS. *see* surface-enhanced Raman scattering (SERS)
 SFGP. *see* substrate-free gas phase synthesis (SFGP)
 SH21 205
 SI-ARGET ATRP. *see* surface-initiated activators regenerated by electron transfer atom transfer radical polymerization (SI-ARGET ATRP)
 SI-ATRP. *see* surface-initiated atom transfer radical polymerization (SI-ATRP)
 side-chain-initiated polymerization 59
 silica (SiO₂) 425
 silicon (Si) 457–458
 silicon nanowire arrays (SiNWAs) 125
 silver (Ag) 96, 426
 silver nanoparticles (AgNPs) 96, 117, 158, 239, 245, 349, 561, 600
 bacterial resilience against 240–241
 bactericidal impact of 242–243
 biogenic silver nanoparticles 243–244
 DNA interaction 244–245
 modes of antimicrobial effectiveness and resistance 241, 241
 silver tetrafluoroborate (AgBF₄) 55
 singlet oxygen (¹O₂) 450
 single-walled carbon nanotubes (SWCNTs) 278
 skin and soft tissue infections (SSTIs) 561
 skin infection 553
 advantages of MNs in managing 558
 increasing permeation of antimicrobials in biofilms 558–560
 MNs used to treating skin infections without wounds 561–566
 monitoring pharmacokinetics of antibiotics 560–561
 sonodynamic sterilization materials for 463–465
 slippery porous lubricant-infused surface (SLIPS) 119, 591
 SLIPS. *see* slippery porous lubricant-infused surface (SLIPS)
 small-molecule photosensitizers 388–389
 for photodynamic antibacterial uses 390–394
 smart antibacterial surfaces. *see also* bifunctional antibacterial surfaces
 based on “kill and release” strategy 123–132
 with light responsivity 129–130, 129
 with pH responsivity 125–127, 126, 127
 with salt responsivity 127–129, 128
 with stimuli responsivity 130–132, 131, 132
 with temperature responsivity 123–125, 124
 smart antimicrobial surfaces 99–103, 101, 102, 601, 602, 603, 604

- smart antimicrobial surfaces (*Cont.*)
- with active responsiveness 605
 - bacteria-responsive antimicrobial surfaces 601–605
 - with reversible switching between anti-adhesive and bactericidal properties 605–606
 - with self-cleaning function 606–607
- SMT. *see* sonomechanical therapy (SMT)
- SNAP. *see* S-nitroso-N-acetylpenicillamine (SNAP)
- SNAPP. *see* structurally nanoengineered antimicrobial peptide polymer (SNAPP)
- SNHL. *see* sensorineural hearing loss (SNHL)
- S-nitroso-N-acetylpenicillamine (SNAP) 97
- S-nitrosothiols (RSNO) 372, 373
- sodium acrylate (AANA) 119
- sodium alginate (SA) 404
- sodium oxide alginate (OSA) 96
- soft lithographic method 542
- sol-gel method 146, 535, 596
- solid MNs 556
- solution blowing spinning 288–289
- solvent-nonsolvent method 149
- sonodynamic sterilization materials
- advantages of sonodynamic antibiosis and strategies 453–454
 - application of 463–471
 - categories of 454
 - delivery systems for 458–463
 - inorganic sonosensitizers 456–457
 - organic sonosensitizers 454–456
 - potential antimicrobial mechanisms of 450–451
 - sonomechanical effects 451–452, 451
 - sonothermal damage 452–453
 - synthesis of 454–463
- sonodynamic therapy (SDT) 424, 435, 449–450, 563
- potential antimicrobial mechanisms and advantages of 450–454
 - sonodynamic antibiosis and strategies to improve SDT performance 453–454
 - synergistic photothermal-sonodynamic therapy 438
- sonomechanical therapy (SMT) 450
- sonopiezoelectric therapy (SPT) 450
- sonosensitizers 450, 453
- effectiveness of 454
 - inorganic 456–457
 - organic 454–456
- sonothermal damage 452–453
- sonothermal therapy (STT) 450
- effectiveness of 452
- SP. *see* *Spirulina platensis* (SP)
- sparfloxacin (SPFX) 456
- SPFX. *see* sparfloxacin (SPFX)
- spin-coating method 535
- spin-trapping EPR technique 543
- Spirulina platensis* (SP) 404
- SPR. *see* surface plasmon resonance (SPR)
- SPT. *see* sonopiezoelectric therapy (SPT)
- SSF. *see* submerged or solid-state fermentation (SSF)
- SSSAF. *see* self-supporting smart air filter (SSSAF)
- SSTIs. *see* skin and soft tissue infections (SSTIs)
- Staphylococcus aureus* 379
- star-shaped cationic antimicrobial polymers 59–62, 61
- stencil-making method 149
- steric hindrance 86
- sterilizing coating 155
- chemotherapy-based superhydrophobic antibacterial surfaces 158–161
 - mechanical therapy sterilization 155–158, 158
 - phototherapy-based superhydrophobic antibacterial surfaces 161–163
- stimuli responsivity, smart antibacterial surfaces
- with 130–132, 131, 132
- Streptococcus mutans* 10–11
- streptogramins 231
- Streptomyces roseosporus* 183
- streptomycin 241, 484
- structurally nanoengineered antimicrobial peptide polymer (SNAPP) 195–196
- STT. *see* sonothermal therapy (STT)
- S-type heterojunctions 537
- styrene derivatives 37
- submerged or solid-state fermentation (SSF) 211
- submicro/micropillars 151
- substrate-free gas phase synthesis (SFGP) 327
- sulfobetaine (SB) 87
- sulfobetaine-3,4-ethylenedioxythiophene (SBEDOT) 130
- sulfobutyl ether- β -cyclodextrin (SCD) 562
- sulfonamide-conjugated PU (SA-PU) polymer 603
- sulfonamides 233, 241
- sulfonated reduced graphene oxide (rGO-SO₃) 500
- sulfones 233
- sulfonium-based cations 54–55, 55
- superconductivity of 2D TMDs 343
- superhydrophilic surface 152
- superhydrophobic antifouling and antimicrobial materials 139
- antibacterial adhesion coating 153–155
 - application 163–168
 - bacterial adhesion, factors influencing 151–152
 - bioinspired surfaces 140–142
 - building construction 167–168
 - marine shipping 165–167
 - medical and health industry 163–165, 165, 166
 - methods for preparing superhydrophobic surfaces 144–150
 - sterilizing coating 155–163
 - types of 152–163

- wettability, theories of 142–144, 143
- superhydrophobic surfaces 114, 139, 152
- chemical vapor deposition 146–147, 147
 - direct film formation 149–150
 - electrochemical method 147–148
 - etching 146
 - heterogeneous nucleation 144–145, 144–145
 - layer-by-layer deposition 148, 148
 - methods for preparing 144–150, 150
 - plasma processing 145
 - self-assembly method 149
 - sol–gel route 146
 - solvent–nonsolvent method 149
 - template method 149
- superoxide anion radical ($\cdot\text{O}_2^-$) 450
- surface-enhanced Raman scattering (SERS) 335
- surface graft copolymerization 89
- surface-initiated activators regenerated by electron transfer atom transfer radical polymerization (SI-ARGET ATRP) 94
- surface-initiated atom transfer radical polymerization (SI-ATRP) 90
- surface-initiated photoiniferter-mediated polymerization (SI-PIMP) strategy 93
- surface-initiated polymerization 89
- surface-initiated reversible addition-fragmentation chain-transfer polymerization reaction (SI-RAFT) 90
- surface modification of materials 85
- surface plasmon resonance (SPR) 293–294
- SWCNTs. *see* single-walled carbon nanotubes (SWCNTs)
- synergistic antibacterial effects 296–298, 297
- synergistic photothermal chemotherapy 435–436
- synergistic
- photothermal-immunotherapy 438–440
- synergistic photothermal-photodynamic/photocatalytic therapy 436–437
- synergistic photothermal-sonodynamic therapy 438
- synthetic AMPs, 183. *see also* natural AMPs
- challenges and solutions 185
 - development of 184–185
- synthetic polymers 405–406, 557
- t**
- tachyplesin 180
- tannic acid (TA) 117
- tannic acid/iron (TA/Fe) 117
- targeted drug delivery, piezoelectric materials
- application in 516–519
- target site binding 65
- TCC. *see* tricarboxylic cellulose (TCC)
- TDM. *see* therapeutic drug monitoring (TDM)
- TEM. *see* transmission electron microscopy (TEM)
- temperature responsivity, smart antibacterial surfaces with 123–125, 124
- template-based studies 184
- template method 149, 285–286
- template strategy 192
- TENG. *see* triboelectric nanogenerator (TENG)
- tert-butyloxycarbonyl group (Boc) 41
- tetracycline (TC) 231, 241, 484
- tetrad(4-pyridyl)-porphyrin (TPyP) 562
- tetraethyl ethylene (TEE) 335
- tetra(4-hydroxyphenyl)porphyrin 60
- 5,10,15,20-tetrakis-(4-methoxycarbonylphenyl)porphyrin (TCPP) 397
- tetramethylpyridinium porphyrin (TMPyP) 404
- textile industry, protease antibacterial materials
- in 213–214
- TFA. *see* trifluoroacetic acid (TFA)
- therapeutic drug monitoring (TDM) 560
- θ -defensins 180
- THFS. *see* trichloro(1H, 1H, 2H, 2H-heptadecafluorodecyl)silane (THFS)
- thin-film hydration technique 458
- thioamides 234
- three-dimensional (3D)
- metal-organic frameworks 276
 - printed orthopedic implant models 596
 - printing technology 600–601
- tissue regeneration, MOF-based antimicrobial substrates for 267
- titanium dioxide (TiO_2) 247, 456, 532
- NPs 239
 - photocatalytic mechanisms in TiO_2 interfaces 535–537
- titanium dioxide nanotubes (TNTs) 428
- titanium oxide 247
- TLR4. *see* toll-like receptor 4 (TLR4)
- TLRs. *see* toll-like receptors (TLRs)
- TMAO. *see* trimethylamine N-oxide (TMAO)
- TMOs. *see* transition metal oxides (TMOs)
- TMSs. *see* transition metal sulfides (TMSs)
- TNTs. *see* titanium dioxide nanotubes (TNTs)
- tobramycin 241
- toll-like receptor 4 (TLR4) 66
- toll-like receptors (TLRs) 567
- top-down synthesis methods of nanomaterials 282, 283
- traditional antimicrobial materials 323
- traditional disinfection methods 538
- traditional quaternary ammonium-based polymers 5
- transition metal-based photothermal materials 427–428
- transition metal carbonitrides 456
- transition metal nitrides/carbides 323
- transition metal oxides (TMOs) 427
- transition metal sulfides (TMSs) 427
- transmission electron microscopy (TEM) 51
- triblock copolymers 57
- triboelectric nanogenerator (TENG) 333

- tricarboxylic cellulose (TCC) 494
 trichloro(1H,1H,2H,2H-heptadecafluorodecyl)
 silane (THFS) 406
 trifluoroacetic acid (TFA) 41
 trimethoprim **241**
 trimethylamine N-oxide (TMAO) 86
 tuberactinomycins **231**
 tumor treatment 304–306, 305
 turmeric-derived CDs 407
 two-dimensional antimicrobial materials
 antimicrobial mechanism of 324
 black phosphorus 345–349
 diagram of 324
 graphdiyne 333–339
 graphene 325–333
 MXenes 353–356
 2D transition metal elements 339–346
 VP 350–352
 two-dimensional polymer brushes 590
 2D transition metal elements (2D TMDs) 323, 339
 antimicrobial applications of 343–346
 electronic properties and optical properties 342
 ferromagnetic properties 342
 liquid-phase exfoliating 341
 mechanical exfoliation 339–341
 preparation of 339
 properties of 342
 structure of 339
 superconductivity 343
 vapor-phase deposition technology 341–342
 “two-step” polymerization 116
 type II heterojunctions 537
 tyrothricin 179
- U**
 UCNP. *see* up-conversion NPs (UCNPs)
 UDPB. *see* upconversion dual-photosensitizer-
 expressing bacteria (UDPB)
 UF. *see* ultrafiltration (UF)
 ultrafiltration (UF) 493
 ultrasonic exfoliating method 341
 ultrasound (US) 485
 activated therapy 568–569
 assisted LPE for violet phosphorus 352
 ultraviolet (UV) 395, 590
 illumination 543
 irradiation 116, 286, 543
 light 149
 UV-responsive TiO₂ surfaces 535–536
 unsaturated lipids 538
 upconversion dual-photosensitizer-expressing
 bacteria (UDPB) 408
 up-conversion NPs (UCNPs) 407
 uranyl salts 532
 ureteral stent implants 617
 ureteral stenting procedure 620–621, 621
 urinary tract infections (UTIs) 470, 617
- US. *see* ultrasound (US)
 US Center for Disease Control and Prevention
 (CDC) 230
 UTIs. *see* urinary tract infections (UTIs)
 UV. *see* ultraviolet (UV)
- V**
 valence band (VB) 436, 533
 vanadium disulphide nanosheets (VS₂ NSs) 341
 vancomycin (VCM) 517, 560, 562
 vapor-phase deposition technology 341–342
 VB. *see* valence band (VB)
 VBSB. *see* vinylbenzyl sulfobetaine (VBSB)
 VCM. *see* vancomycin (VCM)
 vertebrate AMP 180
 verteporfin (VP) 402, 571
 vinylbenzyl sulfobetaine (VBSB) 90
 vinylimidazole compounds 37
 4-vinylpyridine 121
 violet phosphorus (VP), 323, 350. *see also* black
 phosphorus (BP)
 antimicrobial applications of 352
 chemical properties 352
 mechanical exfoliation 352
 preparation of 351–352
 properties of 352
 structure of 350–351, 351
 ultrasound assisted LPE 352
Virgibacillus sp. strain CD6 206
 virtual screening 185
 visible-light photocatalysis, engineering
 semiconductors for 536–537
 VOC. *see* volatile organic compounds (VOC)
 volatile organic compounds (VOC) 498
 VP. *see* violet phosphorus (VP)
- W**
 wastewater reuse 540
 waterborne pathogens 541
 water strider leg 140–141
 Wenzel’s model 142–143
 wettability
 Cassie–Baxter model 143–144
 theories of 142, 143
 Wenzel’s model 142–143
 Young’s equation 142
 white phosphorus (WP), 347. *see also* black
 phosphorus (BP); violet phosphorus (VP)
 WHO. *see* World Health Organization (WHO)
 WIPSS. *see* wireless implantable passive strain
 sensor (WIPSS)
 wireless implantable passive strain sensor
 (WIPSS) 513
 wireless technology, piezoelectric materials
 application in 519–520, 521
 World Health Organization (WHO) 113, 275, 531
 wound dressings

MOF-based antimicrobial substrates for
 265–267, 265, 266
 with Pd nanoparticles 427
 piezoelectric materials used in 501–502
 wound healing 570
 wound management 405
 WP. *see* white phosphorus (WP)

x

Xanthomonas campestris 8

y

Young's equation 142

z

zeolitic imidazolate framework (ZIF) 397
 zeolitic imidazolate framework-8 (ZIF-8) 509
 ZIF-8-integrated MNs 565–566
 zero-dimensional (0D) metal-based
 nanoparticles 276
 ZIF. *see* zeolitic imidazolate framework (ZIF)
 ZIF-8. *see* zeolitic imidazolate framework-8 (ZIF-8)
 zinc oxide (ZnO) 247, 532
 NPs 239

z-scheme heterojunctions 537
 zwitterionic and bactericide synergistic
 antibacterial surface 99, 99
 zwitterionic and cationic polymer synergistic
 antibacterial surface 93–94, 93, 95
 zwitterionic and nitric oxide synergistic
 antibacterial surface 97–98, 98
 zwitterionic polymers 85–86
 antibacterial surface based on antifouling
 property 88–91
 characteristics 87–88
 smart antimicrobial surfaces 99–103
 zwitterionic polymers-based antibacterial
 surface 88–103
 zwitterions 86
 and antimicrobial peptide synergistic
 antibacterial surface 94, 96
 characteristics 87–88
 dipole moment and hydration 88
 DMAPMAPS 91
 and metal synergistic antibacterial
 surface 94–97
 molecular structure 87

